Psilocybin clinical trials for cancer patients

The Psilocybin clinical trials for cancer patients at New York University and Johns Hopkins became a conspicuous turning point in the return of psychedelic therapy to mainstream research. In 2016, the two studies were published together with results suggesting that a single Psilocybin session could accompany clinically significant, sustained reductions in anxiety and depression for many people facing cancer. The findings attracted broad professional attention, but their force lay in a promise still requiring confirmation: the trials were small, and neither striking outcomes nor participants’ reports of mystical experience could settle questions of efficacy, mechanism, and generalizability.

Why cancer patients became a focus

Researchers Stephen Ross and Griffiths had concentrated on cancer patients in part because they believed it would be easier to obtain approval to study a controlled substance among people who were already seriously ill or dying. That practical strategy placed existential distress and psychiatric symptoms in a particularly consequential setting. The studies addressed anxiety and depression in people confronting cancer, rather than presenting Psilocybin as a general remedy detached from patients’ circumstances.

The 2016 publication also marked a shift in institutional reception. The New York Times gave the results front-page coverage in December, and the studies appeared together in a special issue of the Journal of Psychopharmacology. Nearly a dozen accompanying commentaries came from prominent figures in mental health, including two former presidents of the American Psychiatric Association. The framing had moved well beyond a narrowly technical report: the research had become a public test of whether psychedelic treatment could again be discussed as serious clinical work.

Reported outcomes and their duration

Across the two trials, approximately 80 percent of cancer patients showed clinically significant reductions on standard measures of anxiety and depression. The reported benefits endured for at least six months after the Psilocybin session. The duration mattered: the account did not describe only a brief change in mood immediately following treatment, but an improvement that remained evident over a period of months.

The effect sizes were also unusually large by the comparison offered in the book. For most outcome measures in the cancer studies, statistical effect sizes were at or above 1.0. The initial clinical trials of SSRI antidepressants, by contrast, had effect sizes of about 0.3—sufficient at the time for approval, but markedly smaller. This comparison conveys why the results drew attention; it is not a head-to-head trial showing that Psilocybin outperformed antidepressants. The cancer studies were notable signals within their own measures, not a direct comparative verdict on available treatments.

A second finding concerned the relationship between subjective experience and symptom change. In both studies, the reported intensity of the mystical experience closely correlated with the degree to which participants’ symptoms subsided. That association made the experiential dimension central to interpretation: the treatment’s apparent clinical benefit coincided with experiences participants described as especially intense and spiritually significant. Correlation, however, does not establish that mystical intensity caused the improvement. The results identified a relationship worth investigating, not a settled account of how the treatment produced its effects.

Reception, access, and the limits of the evidence

The response within mental health institutions was cautiously encouraging. The combined studies included only about eighty subjects, and the account stresses that the findings would need to be repeated on a larger scale before the government could consider rescheduling Psilocybin and approving the treatment. The results nonetheless prompted interest: dozens of medical schools sought to join future trials, and funders came forward to support further research. After decades in which psychedelic therapy had occupied the margins, the field was becoming respectable again, though not yet established.

New York University’s changing posture made that transition concrete. The university had once tolerated the work somewhat grudgingly, but after the results it promoted the study proudly and invited Stephen Ross to move his treatment room from the dental college into the main hospital. The relocation signaled institutional recognition, not regulatory approval or proof that the treatment was ready for routine use. The distinction matters: favorable attention and a path toward expanded research arrived before the larger trials required to establish whether the early outcomes would hold.

The book places this excitement against a longer history of promising psychedelic research and disappointing attempts at replication. In Saskatchewan, clinicians treating people with alcohol dependence came to regard LSD as highly successful, while a later Toronto replication used neutral rooms, limited clinician engagement, and extensive questionnaires in an effort to isolate the drug’s effects. Its outcomes did not match the Saskatchewan results, and some volunteers had frightening experiences. The disagreement exposed how the conditions surrounding a session could shape both experience and interpretation. It is not evidence about the cancer trials themselves, but it cautions against treating clinical results as separable from study design and therapeutic context.

Criticism and the next research questions

The cancer findings also faced methodological criticism. James Coyne raised objections concerning the size and composition of the patient group, the reliability of diagnoses, placebo control, blinding, and the theoretical assumptions behind the studies. He also questioned whether existential or spiritual well-being should be treated as a psychiatric issue. These challenges concern more than statistical technique: they ask what kind of suffering the trials were measuring and what would count as a medical response to it.

The small samples left room for several explanations that larger studies would need to examine. Early research can select volunteers who seem especially likely to respond; small groups can receive unusually attentive care from highly trained therapists; and expectations surrounding a new treatment may contribute to reported effects. The book therefore treats the results as promising signals rather than definitive proof of cure. A substantial and persistent signal deserves follow-up, but its size in an early study cannot simply be assumed to predict the same outcome in a broader population.

The cancer trials also formed part of a wider resurgence rather than an isolated endpoint. In Europe, regulators considering Psilocybin for anxiety and depression in people with life-changing diagnoses pointed not only to the New York University and Johns Hopkins findings but also to a small Imperial College study of treatment-resistant depression. That separate study had no control group, illustrating the preliminary character of the emerging evidence across conditions. The cancer results helped make further inquiry plausible; they did not answer whether the same treatment would work across different diagnoses or settings.

The trials’ significance thus rests in a tension between remarkable outcomes and unresolved evidence. Their reported reductions in anxiety and depression lasted at least six months, and their publication drew researchers, institutions, and funders back toward a once-marginal field. At the same time, small samples, methodological questions, and the uncertain relationship between mystical experience and symptom relief kept the conclusions provisional. The work reopened a clinical question; it did not close it.